AR059688A1 - Uso de alfa - toxina para tratar y prevenir las infecciones por staphylococcus - Google Patents

Uso de alfa - toxina para tratar y prevenir las infecciones por staphylococcus

Info

Publication number
AR059688A1
AR059688A1 ARP070100833A ARP070100833A AR059688A1 AR 059688 A1 AR059688 A1 AR 059688A1 AR P070100833 A ARP070100833 A AR P070100833A AR P070100833 A ARP070100833 A AR P070100833A AR 059688 A1 AR059688 A1 AR 059688A1
Authority
AR
Argentina
Prior art keywords
antigen
toxin
alpha
aureus
staphylococcus
Prior art date
Application number
ARP070100833A
Other languages
English (en)
Inventor
Kimberly L Taylor
All I Fattom
Original Assignee
Nabi Biopharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US81259806P priority Critical
Priority to US87536306P priority
Application filed by Nabi Biopharmaceuticals filed Critical Nabi Biopharmaceuticals
Publication of AR059688A1 publication Critical patent/AR059688A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/085Staphylococcus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507Comprising a combination of two or more separate antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55577Saponins; Quil A; QS21; ISCOMS
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6037Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/70Multivalent vaccine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

Vacunas que comprenden un antígeno de alfa-toxina de S. aureus y un vehículo aceptable para el uso farmacéutico, y que son utiles para tratar y prevenir infecciones. El antígeno de alfa-toxina de S. aureus puede contener al menos dos alteraciones que reducen su toxicidad, y/o puede estar conjugado o puede co-administrarse con otro antígeno bacteriano. Las vacunas pueden comprender uno o más antígenos bacterianos adicionales. También se proporcionan composiciones de anticuerpos que comprenden anticuerpos contra la alfa-toxina, y opcionalmente uno o más antígenos bacterianos adicionales, y que son utiles para tratar y prevenir infecciones. Reivindicacion 1: Una composicion de antígenos estafilococica pentavalente que comprende (i) un antígeno de Tipo 5 de S. aureus, (ii) un antígeno de Tipo 8 de S. aureus, (iii) un antígeno 336 de S. aureus, (iv) un antígeno de alfa-toxina de S. aureus y (y) un antígeno de leucocidina estafilococica.
ARP070100833A 2006-06-12 2007-02-28 Uso de alfa - toxina para tratar y prevenir las infecciones por staphylococcus AR059688A1 (es)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US81259806P true 2006-06-12 2006-06-12
US87536306P true 2006-12-18 2006-12-18

Publications (1)

Publication Number Publication Date
AR059688A1 true AR059688A1 (es) 2008-04-23

Family

ID=38278910

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070100833A AR059688A1 (es) 2006-06-12 2007-02-28 Uso de alfa - toxina para tratar y prevenir las infecciones por staphylococcus

Country Status (12)

Country Link
US (2) US20080131457A1 (es)
EP (2) EP2719397A1 (es)
JP (2) JP2009539979A (es)
KR (1) KR20090019007A (es)
CN (2) CN102743747A (es)
AR (1) AR059688A1 (es)
AU (1) AU2007259415B2 (es)
CA (1) CA2655133C (es)
MX (1) MX2008015814A (es)
NZ (2) NZ597046A (es)
TW (1) TW200744632A (es)
WO (1) WO2007145689A1 (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020092987A1 (en) * 1998-09-05 2002-07-18 Taehee Cho Photo detect device using quantum dots and materialization method thereof
AU2005324448A1 (en) * 2005-01-10 2006-07-20 Glaxosmithkline Biologicals Sa Method of treating Staphylococcus aureus infection
EP2289938A3 (en) * 2005-06-13 2011-04-06 GlaxoSmithKline Biologicals S.A. Use of Panton-Valentine Leukocidin for treating and preventing staphylococcus infections
AU2007281934B2 (en) * 2006-01-18 2012-11-15 University Of Chicago Compositions and methods related to Staphylococcal bacterium proteins
US8124107B2 (en) * 2006-02-22 2012-02-28 The Texas A&M University System Antibodies recognizing a highly expressed putative antigen of CA-MRSA and methods of use
US20180221466A9 (en) * 2006-06-12 2018-08-09 Glaxosmithkline Biologicals S.A. Use of alpha-toxin for treating and preventing staphylococcus infections
EP2719397A1 (en) * 2006-06-12 2014-04-16 GlaxoSmithKline Biologicals SA Use of alpha-toxin for treating and preventing staphylococcus infections
JP2008013447A (ja) * 2006-07-03 2008-01-24 Juntendo 毒素検出方法
US9181329B2 (en) 2007-08-31 2015-11-10 The University Of Chicago Methods and compositions related to immunizing against Staphylococcal lung diseases and conditions
CN105367656A (zh) * 2007-08-31 2016-03-02 芝加哥大学 与针对葡萄球菌性肺部疾病和病症进行免疫相关的方法和组合物
US20110044968A1 (en) * 2008-03-10 2011-02-24 Pharmal N Corporation Compositions for treatment with metallopeptidases, methods of making and using the same
WO2010014304A1 (en) * 2008-07-29 2010-02-04 University Of Chicago Compositions and methods related to staphylococcal bacterium proteins
EP2208787A1 (en) 2009-01-19 2010-07-21 Université de Liège A recombinant alpha-hemolysin polypeptide of Staphylococcus aureus, having a deletion in the stem domain and heterologous sequences inserted
SI2414387T1 (sl) 2009-04-03 2016-01-29 University Of Chicago KOMPOZICIJE IN POSTOPKI, POVEZANI Z VARIANTAMI PROTEINA A (SpA)
US8679505B2 (en) 2009-04-14 2014-03-25 Novartis Ag Compositions for immunising against Staphylococcus aureus
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
EP2284193A1 (en) 2009-08-10 2011-02-16 Kenta Biotech AG Human monoclonal antibody against S. aureus derived apha-toxin and its use in treating or preventing abscess formation
ES2626416T3 (es) 2009-10-30 2017-07-25 Glaxosmithkline Biologicals Sa Purificación de sacáridos capsulares de Staphilococcus aureus de tipo 5 y de tipo 8
MX364642B (es) * 2010-05-05 2019-05-03 Univ New York LEUCOCIDINS FROM STAPHYLOCOCCUS AUREUS, THERAPEUTIC COMPOSITIONS AND USES OF THE SAME.
AU2011274367B2 (en) 2010-07-02 2015-04-23 The University Of Chicago Compositions and methods related to protein A (SpA) variants
CA2825770A1 (en) 2011-02-08 2012-08-16 Integrated Biotherapeutics, Inc. Immunogenic composition comprising alpha-hemolysin oligopeptides
CN103443285B9 (zh) * 2011-02-08 2018-04-24 米迪缪尼有限公司 特异性结合金黄色葡萄球菌α毒素的抗体以及使用方法
CN103561762A (zh) * 2011-03-16 2014-02-05 明尼苏达大学董事会 诱导针对葡萄球菌属中细菌的免疫应答的组合物和方法
US8945588B2 (en) 2011-05-06 2015-02-03 The University Of Chicago Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
CA2839558A1 (en) * 2011-06-19 2012-12-27 New York University Leukotoxin e/d as a new anti-inflammatory agent and microbicide
HUE051832T2 (hu) * 2011-06-19 2021-03-29 Univ New York Staphylococcus aureus fertõzések és a kapcsolódó állapotok kezelésére és megelõzésére szolgáló módszerek
MX2014002363A (es) 2011-09-01 2014-04-14 Novartis Ag Formulaciones de antigenos de staphylococcus aureus con adyuvante.
CN104023744A (zh) 2011-12-23 2014-09-03 诺华股份有限公司 用于针对金黄色葡萄球菌免疫的稳定组合物
PL2668208T3 (pl) * 2012-04-17 2015-12-31 Arsanis Biosciences Gmbh Cross-reactive antibody recognizing Staphylococcus aureus
KR102288394B1 (ko) * 2012-11-06 2021-08-09 메디뮨 엘엘씨 스타필로코커스 아우레우스 표면 결정인자에 대한 항체
KR20150092738A (ko) 2012-11-06 2015-08-13 메디뮨 엘엘씨 에스.아우레우스 연관 질병의 치료 방법
RU2015154792A3 (es) * 2013-05-21 2018-03-21
GB201310008D0 (en) * 2013-06-05 2013-07-17 Glaxosmithkline Biolog Sa Immunogenic composition for use in therapy
EP3848046A1 (en) * 2013-06-18 2021-07-14 New York University Pharmaceutical compositions containing a mutated leukocidin e
CA2925071A1 (en) * 2013-10-17 2015-04-23 Arsanis Biosciences Gmbh Cross-reactive staphylococcus aureus antibody sequences
RS59971B1 (sr) 2014-03-26 2020-03-31 Glaxosmithkline Biologicals Sa Mutantni stafilokokni antigeni
WO2016044588A1 (en) 2014-09-19 2016-03-24 The Regents Of The University Of Michigan Staphylococcus aureus materials and methods
US10668141B2 (en) * 2015-08-10 2020-06-02 Kyoto Biken Laboratories, Inc. Vaccine containing inactivated cells of Staphylococcus aureus mixed with leucocidin
CN108367062A (zh) 2015-10-13 2018-08-03 赛诺菲巴斯德有限公司 抗金黄色葡萄球菌的免疫原性组合物
CN105646681B (zh) * 2016-01-21 2021-07-16 浙江海隆生物科技有限公司 一种奶牛金黄色葡萄球菌α-溶血素亚单位疫苗的制备方法及应用
CN105641689A (zh) * 2016-01-21 2016-06-08 浙江海隆生物科技有限公司 一种奶牛金黄色葡萄球菌β-溶血素亚单位疫苗的制备方法及应用
CN105695357A (zh) * 2016-03-18 2016-06-22 辽宁成大生物股份有限公司 一种筛选高产α毒素的金黄色葡萄球菌菌株方法
TW201837054A (zh) 2017-01-03 2018-10-16 美商再生元醫藥公司 抗金黃色葡萄球菌,溶血素a毒素之人類抗體
CN107224575B (zh) * 2017-03-06 2018-11-09 浙江海隆生物科技有限公司 奶牛金黄色葡萄球菌乳房炎亚单位疫苗的组合物及其制备方法和应用
CN112538112A (zh) * 2019-09-20 2021-03-23 迈威(上海)生物科技股份有限公司 抗α-溶血素的抗体及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4327082A (en) * 1979-07-12 1982-04-27 Adcock-Ingram Laboratories Limited Mastitis vaccination
CA2123811C (en) 1991-11-22 2005-07-05 Ali Ibrahim Fattom Type i and type ii surface antigens associated with staphylococcus epidermidis
US6294177B1 (en) 1996-09-11 2001-09-25 Nabi Staphylococcus aureus antigen-containing whole cell vaccine
US5770208A (en) * 1996-09-11 1998-06-23 Nabi Staphylococcus aureus B-linked hexosamine antigen
US6703025B1 (en) * 1998-08-31 2004-03-09 Inhibitex, Inc. Multicomponent vaccines
ES2321892T3 (es) 1998-09-14 2009-06-12 Nabi Biopharmaceuticals Composiciones de beta-glucanos e inmunoglobulinas especificas.
US6936258B1 (en) 1999-03-19 2005-08-30 Nabi Biopharmaceuticals Staphylococcus antigen and vaccine
US6849259B2 (en) 2000-06-16 2005-02-01 Symphogen A/S Polyclonal antibody composition for treating allergy
NZ553775A (en) * 2004-09-22 2010-05-28 Glaxosmithkline Biolog Sa Immunogenic composition for use in vaccination against staphylococcei
US20060134141A1 (en) * 2004-12-14 2006-06-22 Nabi Biopharmaceuticals Glycoconjugate vaccines containing peptidoglycan
AU2005324448A1 (en) * 2005-01-10 2006-07-20 Glaxosmithkline Biologicals Sa Method of treating Staphylococcus aureus infection
DK1838341T3 (da) * 2005-01-20 2013-11-04 Isconova Ab Vaccinesammensætning omfattende et fibronectin bindende protein eller et fibronectinbindende peptid
EP2289938A3 (en) * 2005-06-13 2011-04-06 GlaxoSmithKline Biologicals S.A. Use of Panton-Valentine Leukocidin for treating and preventing staphylococcus infections
EP2719397A1 (en) * 2006-06-12 2014-04-16 GlaxoSmithKline Biologicals SA Use of alpha-toxin for treating and preventing staphylococcus infections

Also Published As

Publication number Publication date
TW200744632A (en) 2007-12-16
JP2013151526A (ja) 2013-08-08
US20090053235A1 (en) 2009-02-26
AU2007259415A1 (en) 2007-12-21
CN102743747A (zh) 2012-10-24
EP2719397A1 (en) 2014-04-16
EP2043690A1 (en) 2009-04-08
KR20090019007A (ko) 2009-02-24
CN101466406A (zh) 2009-06-24
CA2655133A1 (en) 2007-12-21
CN101466406B (zh) 2012-06-27
MX2008015814A (es) 2009-01-12
NZ597046A (en) 2014-01-31
JP2009539979A (ja) 2009-11-19
US20080131457A1 (en) 2008-06-05
CA2655133C (en) 2018-03-20
AU2007259415B2 (en) 2013-09-26
WO2007145689A1 (en) 2007-12-21
NZ574057A (en) 2012-01-12

Similar Documents

Publication Publication Date Title
AR059688A1 (es) Uso de alfa - toxina para tratar y prevenir las infecciones por staphylococcus
BRPI0906478B8 (pt) anticorpo anti-nr10, seu uso e composição farmacêutica que o compreende
CL2013002417A1 (es) Compuestos derivados de fluoropiridinona; composición farmacéutica que los comprende; y su uso en el tratamiento de infecciones bacterianas.
CL2008000789A1 (es) Compuestos derivados de adenina; composicion farmaceutica que comprende a dichos compuestos, utiles para tratar enfermedades alergicas, virales o cancer, entre otras.
AR089004A1 (es) Composiciones farmaceuticas inyectables, metodo, uso
CL2010000188A1 (es) Metodo para el tratamiento de una infeccion en un sujeto que comprende la administracion de 9-[(2,2-dimetil-propilamino)-metil]-minociclina o de una sal de la misma; composicion farmaceutica que comprende dicho compuesto; y su uso.
NZ595689A (en) Compositions for immunising against staphylococcus aureus
CL2011000558A1 (es) Formas cristalinas de un compuesto derivado de 2-tiazolil-4-quinolinil-oxi; sal de sodio del compuesto, composicion farmaceutica que comprende la sal de sodio, util para tratar una infeccion por el virus de la hepatitis c.
EA200901617A1 (ru) Борсодержащие молекулы небольшого размера
EA033311B1 (ru) Производные бензоксаборола в качестве антибактериальных средств
BRPI0821110B8 (pt) anticorpo de neutralização de anti-nr10/il31ra, composição farmacêutica compreendendo o referido anticorpo e uso do mesmo
TR201807494T4 (tr) Viral enfeksiyon sonrası ikincil enfeksiyonların önlenmesi ve tedavisi.
BRPI0720569B8 (pt) compostos de tetraciclina substituída e uso dos ditos compostos para o tratamento de uma infecção bacteriana, viral ou parasitária
WO2007138116A3 (de) Pharmazeutische zusammensetzung zur behandlung von virusinfektionen und/oder tumorerkrankungen durch inhibition der proteinfaltung und des proteinabbaus
CL2008003788A1 (es) Composicion farmaceutico que comprende a) el anticuerpo b-ly1 humanizado (anti-cd20/antigeno de referenciacion restringida del linfocito b humano/bp35, de tipo ii), b) opcionalmente de 0,001% al 1%p/v de por lo menos un surfactante, y c) de 1 a 100 mm de un tampon; uso para tratar enfermedades relacionadas con cd20.
CL2007001185A1 (es) Formulaciones que estabilizan o inhiben la agregacion inducida por silicona de un conjugado de polisacarido-proteina;formulaciones que estabilizan o inhiben la agregacion inducida por silicona de un conjugado de polisacarido-proteina;formulaciones que estabilizan o inhiben la agregacion inducida por silicona de una composicion de proteina de n meningitidis
BRPI0922435A2 (pt) "composto de tiazolopiridina moduladores de sirtuina, composição farmacêutica compreendendo o mesmo e seu uso."
AR050717A1 (es) Composiciones farmaceuticas
ECSP099634A (es) Derivados de piridazinona útiles como inhibidores de glucano sintasa
UY30778A1 (es) Compuestos de 5,6-dihidro-1h-piridin-2-ona
BRPI0611820B8 (pt) método de identificar uma infecção por e. canis ou e. chaffeensis
TW200734344A (en) Antibacterial agents
BRPI0806863B8 (pt) uso de um éster de forbol na preparação de um medicamento para prevenção ou tratamento de uma infecção por hiv
EA200970916A1 (ru) Соединения 5,6-дигидро-1н-пиридин-2-она
CL2007003232A1 (es) Compuestos derivados de 5-hidroximetil oxazolidin-2-ona; composicion farmaceutica que contiene a dichos compuestos; y su uso para tratar y prevenir infecciones bacterianas.

Legal Events

Date Code Title Description
FC Refusal